多がん早期発見市場調査レポート-最新動向、成長機会、市場規模・シェア世界予測分析-2024年～2033年

Multi-cancer Early Detection Market Size Research Report - Overview

According to a research report on the global multi-cancer early detection market , the market is projected to grow at a CAGR of 16.9 % between 2024 and 2033, and is further projected to generate a market size of USD 4.3 billion by the end of 2033. In 2024, the market size was USD 1.2 billion .

• The global cancer early detection market is expected to grow due to the rising incidence of cancer.
• In Japan, the growth of the multi-cancer early detection market can be attributed to the increasing public awareness towards cancer diagnosis.
• Growth analysis by KDMI analysts predicts that cost and affordability will be the main challenges driving market growth.
• North America, with the highest market share in the multi-cancer early detection market, is expected to dominate the global market

Multi-cancer early detection market analysis

Multi-cancer early detection (MCED) is a test that uses cutting-edge technology to detect multiple types of cancer from a single blood sample. These tests have an excellent ability to detect cancer-related indicators, such as protein markers and gene mutations, before signs and symptoms become noticeable. In recent years, the number of cancer patients has been steadily increasing due to various factors such as unhealthy lifestyle habits, aging, and environmental exposure, which has fueled the multi-cancer early detection market globally. According to the report, there will be approximately 20 million new cases of cancer and 9.7 million deaths due to cancer in 2022. Moreover, by 2050, the burden of cancer will increase by approximately 77%, further worsening healthcare systems, people, and communities.

Analyst's thoughts on Japan's multi-cancer early detection market research

In Japan, the growth of the multi-cancer early detection market is attributed to the rising public awareness towards cancer diagnosis. The growing awareness of the people in the country towards cancer has grown into a strong market growth catalyst with the help of various initiatives, educational campaigns, and changes in the local healthcare landscape. Moreover, dissemination of information through media reports and digital platforms also plays a role in raising awareness regarding the risk of cancer and the importance of early diagnosis. Japan has implemented a nationwide screening program for gastric, colorectal, lung, breast, cervical, and other cancers, which are mainly available in communities and workplaces. All these initiatives are driving the multi-cancer early detection market in Japan.

GENECAST, Singlera Genomics Inc., and Laboratory for Advanced Medicine, Inc. are some of the key players in the multi-cancer early detection market in Japan.

Multi-cancer early detection market: growth drivers and challenges

Growth Drivers

Advances in Data Analytics and Artificial Intelligence (AI):

The introduction of data analytics and artificial intelligence (AI) technologies has dramatically changed cancer detection and diagnosis. These advances have made it easier to process and analyze large amounts of clinical and molecular data, allowing the recognition of complex patterns and abnormalities that indicate malignancies. Specifically, machine learning algorithms have shown the potential to improve the accuracy and efficiency of several cancer screening tests. AI has helped improve the speed, accuracy, and reliability of several cancer screening and detection methods. Medical images like mammograms can be processed in less time with the help of AI, freeing up radiologists to perform other tasks that require their specialized skills. Thus, leveraging AI-driven analytics can help medical professionals make more thoughtful decisions regarding patient risk assessment, screening protocols, and treatment strategies, ultimately enhancing the effectiveness of several cancer early detection programs and improving the fight against cancer.

Constraints

Costs and prices:

One of the main barriers to widespread availability and access to multi-cancer screening tests is their high cost coupled with other associated costs such as follow-up diagnostic procedures. Without adequate reimbursement or insurance coverage for accessing early detection services, many patients may face financial burden and disparities. Furthermore, high expenses may hinder the expansion of the multi-cancer early detection market by minimizing consumers' access to testing services. According to the survey results, the total cost to the healthcare system for initial cancer screening in the United States will be worth $43 billion in 2021. Furthermore, approximately 88.3% of the cost will be attributable to private insurance, 8.5% to Medicare, and 3.2% to Medicaid, other government programs and uninsured individuals.

Multi-cancer Early Detection Market Segmentation

Experts at KD Market Insights have segmented the Global Multi-Cancer Early Detection Market research report into:

Multi-cancer early detection market overview by region

The North American Multiple Cancer Early Detection (MCED) market is driven primarily by increasing number of cancer patients, rising patient awareness, growing innovation in medical technologies, and increasing investments by major market players in early detection of multiple cancer types. The region accounts for approximately 35% of the global market. The United States leads the market in the region due to its significant investments and the presence of a large number of biotechnology companies developing advanced MCED tests. According to data collected by the National Center for Health Statistics, the United States is expected to experience approximately 1,958,310 new cancer cases and 609,820 cancer deaths in 2023.

The Asia-Pacific multiple cancer early detection market is expected to witness the fastest growth, driven by advanced medical infrastructure, a large and growing population, and an increasing number of local companies entering the market. With nearly half of the world's cancer cases and cancer deaths occurring in Asia, the need for early detection solutions is surging. Moreover, it is estimated that there will be 3,246,625 new cancer cases and 1,699,066 deaths in China alone in 2024. Moreover, demographic changes such as urban growth and development, aging population, and economic growth are increasing the importance of cancer prevention.

According to analysts at KD Market Insights, five companies are expected to lead the growth of the North American multi-cancer early detection market:

• Naveris (USA)
• VESEN (USA)
• Grail, LLC (Illumina) (USA)
• Exact Sciences Corporation (USA)
• Foundation Medicine Inc.

Competitive Landscape of Multi-Cancer Early Detection Market

Major companies with the top global market share in the multi-cancer early detection market

• Micronoma
• Anpac Biomedical Sciences (USA)
• Early Diagnostics (USA)
• Early is Good (USA)
• Cansense (USA)
• Freegnome Holdings (USA)
• OncoCyte Corporation (USA)
• Sequin (USA)
• Naveris (USA)
• Bessen Corporation (USA)
• Grail, LLC (Illumina) (USA)
• Exact Sciences Corporation (USA)
• Foundation Medicine (USA)
• Guangzhou Ankerdex Medical Co., Ltd. (China
• Guardant Health (USA)
• Burning Rock Biotech (China)
• Genecast Biotechnology (China)
• Singlera Genomics, Inc.